phone

Iron Deficiency Anemia - Pipeline Review, H2 2017

  • Published Date: 18 Jul 2017
  • Number of Pages: 76
  • Category: Pharmaceuticals
  • Country: Global
Iron Deficiency Anemia - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Iron Deficiency Anemia - Pipeline Review, H2 2017, provides an overview of the Iron Deficiency Anemia (Hematological Disorders) pipeline landscape.

Anemia is a condition in which the body does not have enough healthy red blood cells. Iron helps make red blood cells. When body does not have enough iron, it will make fewer red blood cells or red blood cells that are too small. This is called iron deficiency anemia. Symptoms include feeling grumpy, headaches and problems concentrating or thinking. Treatment includes iron supplements and eating iron-rich foods.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Iron Deficiency Anemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Iron Deficiency Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 2, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Iron Deficiency Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Iron Deficiency Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Iron Deficiency Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Iron Deficiency Anemia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Iron Deficiency Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

Introduction
Global Markets Direct Report Coverage
Iron Deficiency Anemia - Overview
Iron Deficiency Anemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Iron Deficiency Anemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Iron Deficiency Anemia - Companies Involved in Therapeutics Development
Akebia Therapeutics Inc
Galenica Ltd
Novartis AG
Panion & Bf Biotech Inc
Pharmacosmos A/S
Pieris Pharmaceuticals Inc
Rockwell Medical Inc
Shield Therapeutics Plc
Iron Deficiency Anemia - Drug Profiles
AKB-5343 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSJ-137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Replace Iron for Iron Deficiency Anemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric carboxymaltose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric maltol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric pyrophosphate citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hinokitiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iron isomaltoside - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSC-8679 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Activate Erythroferrone for Iron Deficiency Anemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRS-080 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PT-30 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Iron Deficiency Anemia - Dormant Projects
Iron Deficiency Anemia - Product Development Milestones
Featured News & Press Releases
Jun 22, 2017: Shield Therapeutics: Biomarker data presented at British Society of Gastroenterology demonstrates the potential effect of ferric maltol in patients
Apr 24, 2017: American Regent Announces Enrollment of First Patient in Phase 3 Trial to Investigate Injectafer (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency
Mar 20, 2017: Keryx Announces the Largest Medicare Part D Plan Sponsor Added Auryxia to its Medicare Part D Plan Formularies
Mar 08, 2017: Keryx Biopharmaceuticals Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Auryxia (ferric citrate) Tablets
Feb 13, 2017: Pharmacosmoss Diafer accepted for use in NHS Scotland
Jan 12, 2017: Keryx Biopharmaceuticals Announces Publication of Auryxia (ferric citrate) Phase 3 Trial Results for Iron Deficiency Anemia (IDA) in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) in Journal of the American Society of Nephrology
Jan 08, 2017: Keryx Biopharmaceuticals Announces Recent Business Progress and Reviews Corporate Strategy at 35th Annual J.P. Morgan Healthcare Conference
Jan 06, 2017: Shield Therapeutics Provides Business Update
Dec 07, 2016: EFFECT-HF demonstrates a significantly beneficial effect of Ferinject on exercise capacity among patients with chronic heart failure and iron deficiency - confirms findings of previous studies
Nov 17, 2016: Keryx Biopharmaceuticals Announces Multiple Scientific Presentations of Phase 3 Trial Results of Ferric Citrate for Iron Deficiency Anemia (IDA) in Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
Nov 17, 2016: Monofer (Iron Isomaltoside) Launched In India Under Brand Names isofer And jilazo
Oct 14, 2016: Keryx Biopharmaceuticals Announces Presentations of Data at the American Society of Nephrology Kidney Week 2016 Annual Meeting
Sep 07, 2016: Shield Therapeutics Announces Composition of Matter Patent Granted on Feraccru
Aug 19, 2016: Pharmacosmos to initiate large-scale clinical study programme
Jun 17, 2016: Feraccru (ferric maltol) launched in the UK for the treatment of adults with iron deficiency anemia in patients with inflammatory bowel disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development for Iron Deficiency Anemia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Iron Deficiency Anemia - Pipeline by Akebia Therapeutics Inc, H2 2017
Iron Deficiency Anemia - Pipeline by Galenica Ltd, H2 2017
Iron Deficiency Anemia - Pipeline by Novartis AG, H2 2017
Iron Deficiency Anemia - Pipeline by Panion & Bf Biotech Inc, H2 2017
Iron Deficiency Anemia - Pipeline by Pharmacosmos A/S, H2 2017
Iron Deficiency Anemia - Pipeline by Pieris Pharmaceuticals Inc, H2 2017
Iron Deficiency Anemia - Pipeline by Rockwell Medical Inc, H2 2017
Iron Deficiency Anemia - Pipeline by Shield Therapeutics Plc, H2 2017
Iron Deficiency Anemia - Dormant Projects, H2 2017

List Of Figures


Number of Products under Development for Iron Deficiency Anemia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

TrendSights Analysis: Environmental Responsibility - Meeting consumers environmentally conscious expectations Environmental Responsibility is a constituent trend within the Sustainability & Ethics mega-trend. It reflects consumers broadening concern about the global environment

View Report

Iron Deficiency Anemia - Pipeline Review, H2 2017 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Iron Deficiency Anemia - Pipeline Review, H2 2017, provides an overview of the

View Report

TrendSights Analysis: Smart Living - Integrating intuitive technology across consumer lifestyles and within the home environment TrendSights Analysis: Smart Living explores what the trend is, why it is important, who is

View Report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports